153 related articles for article (PubMed ID: 28653108)
21. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
[TBL] [Abstract][Full Text] [Related]
22. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
24. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
[TBL] [Abstract][Full Text] [Related]
25. Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients.
Nowara E; Huszno J
Ann Palliat Med; 2013 Apr; 2(2):71-5. PubMed ID: 25841928
[TBL] [Abstract][Full Text] [Related]
26. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
27. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Meadows KL; Rushing C; Honeycutt W; Latta K; Howard L; Arrowood CA; Niedzwiecki D; Hurwitz HI
Support Care Cancer; 2015 May; 23(5):1311-9. PubMed ID: 25341548
[TBL] [Abstract][Full Text] [Related]
28. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
30. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
Ni C; Fang J; Qian H; Xu Q; Shen F
J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
[TBL] [Abstract][Full Text] [Related]
31. Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Lee BN; Jung S; Darvin ME; Eucker J; Kühnhardt D; Sehouli J; Chekerov R; Patzelt A; Fuss H; Yu RX; Lademann J
Anticancer Res; 2016 Aug; 36(8):4089-93. PubMed ID: 27466518
[TBL] [Abstract][Full Text] [Related]
32. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
Munzone E; Di Pietro A; Goldhirsch A; Minchella I; Verri E; Cossu Rocca M; Marenghi C; Curigliano G; Radice D; Adamoli L; Nolè F
Breast; 2010 Feb; 19(1):33-7. PubMed ID: 19884008
[TBL] [Abstract][Full Text] [Related]
33. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
Hu X; Dong M; Liang X; Liu Z; Li Q
Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
[TBL] [Abstract][Full Text] [Related]
34. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
[TBL] [Abstract][Full Text] [Related]
35. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
36. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects.
Zhu Y; Wang F; Zhao Y; Zheng X
Eur J Hosp Pharm; 2020 Jun; 28(3):124-8. PubMed ID: 32591480
[TBL] [Abstract][Full Text] [Related]
37. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
Pease DF; Peterson BA; Gilles S; Hordinsky MK; Bohjanen KA; Skubitz KM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):217-221. PubMed ID: 31041511
[TBL] [Abstract][Full Text] [Related]
38. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
39. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
Liang G; Ma W; Zhao Y; Liu E; Shan X; Ma W; Tang D; Li L; Niu X; Zhao W; Zhang Q
BMC Cancer; 2021 Apr; 21(1):362. PubMed ID: 33827689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
